Catalog No.: PC-45134Not For Human Use, Lab Use Only.
Iguratimod (TT-614) is an antirheumatic agent that acts as an inhibitor of COX-2 with IC50 of 20 μM, does not inhibit COX-1, also inhibits macrophage migration inhibitory factor (MIF) with IC50 of 6.81 uM.
Iguratimod (TT-614) is an antirheumatic agent that acts as an inhibitor of COX-2 with IC50 of 20 μM, does not inhibit COX-1, also inhibits macrophage migration inhibitory factor (MIF) with IC50 of 6.81 uM.
Iguratimod (TT-614) is a disease-modifying antirheumatic drug that inhibits NF-kappaB (NF-κB) p65 subunit (RelA) phosphorylation and nuclear translocation without affecting IKBα degradation.
Iguratimod (TT-614) inhibits LPS-stimulated production of TNF-α, IL-6, and IL-8 with decreasing mRNA levels (IL-6 and IL-8).
Iguratimod (TT-614) mainly targets Act1 to disrupt the interaction between Act1 and TRAF5 and IKKi in the IL-17 pathway of synoviocytes.
Iguratimod (TT-614) also exhibts selective MIF inhibition in vitro and in vivo.
